Lenalidomide Synthon

Lenalidomide, the active ingredient in Lenalidomide Synthon, is an immunomodulatory drug presented as an oral formulation for oral use. It treats multiple myeloma and myelodysplastic syndromes in adult patients. GNH USA supplies Lenalidomide Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders. Multiple Myeloma: improves progression‑free survival and overall response rates in eligible patients. Myelodysplastic Syndromes (del(5q)): reduces transfusion dependence and improves blood counts in patients with the specific chromosomal deletion.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: lowered neutrophil count increasing infection risk. - Diarrhea: loose stools that may require supportive care. - Nausea: feeling of sickness often managed with anti‑emetics.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophils requiring medical intervention. - Secondary primary malignancies: emergence of new cancers. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or liver injury.

Lenalidomide requires careful monitoring and specific safety measures before and during therapy. Pregnancy Contraindication: drug is classified as Category X and must not be used during pregnancy. Teratogenic Risk: strict contraceptive measures are required for both male and female patients of reproductive potential. Blood Count Monitoring: regular CBC tests to detect neutropenia or thrombocytopenia. Thrombotic Risk Assessment: evaluate history of clotting disorders before initiating therapy. Renal Impairment Adjustment: dose may need modification in patients with reduced kidney function. Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce drug exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide levels. - NSAIDs (e.g., ibuprofen): can heighten bleeding risk. - P‑gp inhibitors (e.g., verapamil): may raise systemic exposure and require monitoring.